On March 14th, Glonghui reported that Nanjing Pharmaceutical (600713.SH) announced that to meet the company's digital transformation needs and enhance its core competitiveness, the company's controlling shareholder, New工 Investment Group, and its controlling subsidiary, Gold Peak, plan to jointly increase the capital of the company's wholly-owned subsidiary, Zhongjian Information, at a price of 4.489053 yuan per share. New工 Investment Group will increase the capital by 33.007745 million yuan, of which 7.352941 million yuan will be included in the registered capital, and the remaining 25.654804 million yuan will be credited to the capital reserve; Gold Peak will increase the capital by 31.687435 million yuan, of which 7.058824 million yuan will be included in the registered capital, and the remaining 24.628611 million yuan will be credited to the capital reserve; the company will not participate in this capital increase. (The final amounts for the capital increase price and capital reserve will be based on the evaluation results filed with the state-owned asset regulatory authorities.)
After the completion of this capital increase, Zhongjian Information's registered capital will increase from 15 million yuan to 29.411765 million yuan, with the company contributing 15 million yuan, accounting for 51% of its registered capital; New工 Investment Group contributing 7.352941 million yuan, accounting for 25%; and Gold Peak contributing 7.058824 million yuan, accounting for 24%. Zhongjian Information will also be renamed "Nanjing New工 Digital Technology Co., Ltd.".
Comment(0)
Reason For Report